Browsing Tag
Eli Lilly
51 posts
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Are Novo Nordisk layoffs, FDA scrutiny of Hims & Hers, and UnitedHealth profit squeeze reshaping the healthcare sector?
Novo Nordisk layoffs, Hims & Hers FDA warning, and UnitedHealth earnings headwinds shake the healthcare sector. See what investors need to know.
FDA approval of Eli Lilly’s Inluriyo: Can the new oral SERD reshape advanced breast cancer treatment?
FDA clears Eli Lilly’s Inluriyo for ESR1-mutated advanced breast cancer. Explore trial data, stock sentiment, pricing, and future oncology outlook.
Eli Lilly wins European approval for Kisunla, a new Alzheimer’s treatment that targets early symptomatic stages
Eli Lilly wins EU approval for Kisunla, a once-monthly Alzheimer’s therapy that slows decline and reshapes Europe’s treatment landscape.
Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world
GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.